An interventional study of Nasal canula - up to 6 liters per minute and Nasal canula - up to 15 liters per minute in Oxygen Toxicity, COPD Bronchitis and Respiratory Failure, sponsored by Laval University. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Laval University · Not applicable, Interventional, and Supportive care
Among 94 studies in Respiratory Insufficiency with a site in Canada — 24 open to participants now, 29 under way, 1 of them phase 3. Respiratory Insufficiency · Canada.
Among the 94 studies in Respiratory Insufficiency with a site in Canada, this one is the 45th largest by planned enrollment of the 66 interventional ones that give a count, is one of 7 that started in 2024, is one of 46 with no phase, reaches primary completion later than 21 of the 28 other live ones, and was the 84th registered.
1,369 studies on the registry are indexed under Respiratory Insufficiency; 264 are open to participants now.
Browse Respiratory Insufficiency studies →24 of the 94 studies in Respiratory Insufficiency with a site in Canada are open now. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
University of Alberta · Sites in Canada
Laval University · Sites in Canada
Lorenzo delSorbo · Sites in Canada
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 178 Respiratory Insufficiency studies recruiting now, 134 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 12 · Phase 4 1
First in 1995; this study’s year is marked. 7 started in 2024.
This study's planned enrollment of 20 is below the median of 60 across 860 interventional studies indexed under Respiratory Insufficiency.
Median enrollment 31 across the 66 interventional studies, 118 across the 28 observational. Of the 54 that completed or were terminated, 5 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 94 have an industry lead sponsor. The 10 most frequent:
Laval University is the lead sponsor of 380 studies on the registry; 67 are open to participants now.
Laval University has 8 studies filed under Respiratory Insufficiency — fewer than ten, so there is no comparison to draw.
11 of the studies in Respiratory Insufficiency with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07518862University Health Network, TorontoHeart Rate VAriability as a MaRker for tItrATing hIgh flOw Nasal Cannula Therapy | 2026-11 |
| NCT04524585University Health Network, TorontoPartial Neuromuscular Blockade in Acute Hypoxemic Respiratory Failure | 2026-12-01 |
| NCT07359261University of AlbertaTranspulmonary Assessment for Individualized Lung Optimization in Obese Patients | 2026-12-31 |
| NCT07334379Lorenzo delSorboInterleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study | 2027-02-20 |
| NCT05440851University Health Network, TorontoPlatform of Randomized Adaptive Clinical Trials in Critical Illness | 2027-03-31 |
Among the 94 studies in Respiratory Insufficiency with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Oxygen therapy is at the heart of the healthcare system. Oxygen flow rates depend on a number of confounding factors confounding factors (target used, skin pigmentation, pulse oximeter used, etc.) The investigators have recently have recently demonstrated that the combination of these factors (different peripheral oxygen saturation (SpO2) targets and different oximeters) can have a significant impact on oxygen flows rates. The effect on oxygen flow was not simply additive .
The aim of this study is to evaluate the impact of the interface used on oxygen flow rates in different patient populations (main objective). The investigatoers also evaluate the impact of the interface on carbon dioxide (PaCO2), in particular with closed oxygen masks, with which rebreathing is theoretically possible (secondary objective).
secondary objective).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Nasal canula - up to 6 liters per minute · Device: Nasal canula - up to 15 liters per minute · Device: Open oxygen mask · Device: Simple oxygen face mask
Device: Nasal canula - up to 6 liters per minute
Oxygen will be administered via nasal cannula up to 6 liters per minute during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the peripheral oxygen saturation (SpO2) target (92% for non chronic obstructive pulmonary disease (non COPD) patient and 90% for chronic obstructive pulmonary disease (COPD) patient). The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used.
Oxygen will be administered via nasal cannula up to 15 liters per minute during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient). The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used.
Oxygen will be administered via an open during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient). The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used.
Oxygen will be administered via simple oxygen face mask during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient). The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used.
Oxygen flow
Oxygen flows (or fraction of inspired oxygen (FiO2)) at the end of each study period (last minute average) to reach peripheral oxygen saturation (SpO2) target to reach SpO2 target with specific oxygen administration interfaces
Time frame: Mean Oxygen flow in the five last minute of each study period (between minute 10 and 15)
Partial oxygen weaning
Rate of partial oxygen weaning (Oxygen flow \<=0.5 L/min)
Time frame: Mean oxygen flow in the five last minute of each study period (between minute 10 and 15)
Complete oxygen weaning
Rate of complete oxygen weaning (Oxygen flow =0 L/min or FiO2 0.21)
Time frame: Mean oxygen flow in the five last minute of each study period (between minute 10 and 15)
Gaps between the different oximeters
Average of the SpO2 value gaps between the different oximeters tested
Time frame: through period completion, minute 15
Gaps between PaCO2
PaCO2 value at the end of the period
Time frame: through period completion, minute 15
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Jun 2027, 31 months after the start.
Of 359 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 31 months is above that.
Counting every sponsor, half of 375 studies reached it within 24 months; a quarter within 10 and three quarters within 46.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Dec 2024 → Nov 2024, primary completion Jun 2025 → Jun 2027 and completion Dec 2025 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.